Title | Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment. |
Publication Type | Journal Article |
Year of Publication | 2021 |
Authors | Wheeler, DA, Takebe, N, Hinoue, T, Hoadley, KA, Cardenas, MF, Hamilton, AM, Laird, PW, Wang, L, Johnson, A, Dewal, N, Miller, V, Piñeyro, D, de Moura, MCastro, Esteller, M, Shen, H, Zenklusen, JClaude, Tarnuzzer, R, McShane, LM, Tricoli, JV, Williams, PM, Lubensky, I, O'Sullivan-Coyne, G, Kohn, EC, Little, RF, White, J, Malik, S, Harris, L, Weil, C, Chen, AP, Karlovich, C, Rodgers, B, Shankar, L, Jacobs, P, Nolan, T, Hu, J, Muzny, DM, Doddapaneni, H, Korchina, V, Gastier-Foster, J, Bowen, J, Leraas, K, Edmondson, EF, Doroshow, JH, Conley, BA, S Ivy, P, Staudt, LM |
Journal | Cancer Cell |
Volume | 39 |
Issue | 1 |
Pagination | 38-53.e7 |
Date Published | 2021 Jan 11 |
ISSN | 1878-3686 |
Keywords | Antineoplastic Agents, Biopsy, Epigenesis, Genetic, Female, Gene Regulatory Networks, Genetic Variation, Genomics, Humans, Male, Neoplasms, Prognosis, Survival Analysis, Treatment Outcome, Tumor Microenvironment |
Abstract | A small fraction of cancer patients with advanced disease survive significantly longer than patients with clinically comparable tumors. Molecular mechanisms for exceptional responses to therapy have been identified by genomic analysis of tumor biopsies from individual patients. Here, we analyzed tumor biopsies from an unbiased cohort of 111 exceptional responder patients using multiple platforms to profile genetic and epigenetic aberrations as well as the tumor microenvironment. Integrative analysis uncovered plausible mechanisms for the therapeutic response in nearly a quarter of the patients. The mechanisms were assigned to four broad categories-DNA damage response, intracellular signaling, immune engagement, and genetic alterations characteristic of favorable prognosis-with many tumors falling into multiple categories. These analyses revealed synthetic lethal relationships that may be exploited therapeutically and rare genetic lesions that favor therapeutic success, while also providing a wealth of testable hypotheses regarding oncogenic mechanisms that may influence the response to cancer therapy. |
DOI | 10.1016/j.ccell.2020.10.015 |
Alternate Journal | Cancer Cell |
PubMed ID | 33217343 |
PubMed Central ID | PMC8478080 |
Grant List | P30 ES010126 / ES / NIEHS NIH HHS / United States T32 GM122741 / GM / NIGMS NIH HHS / United States U24 CA143843 / CA / NCI NIH HHS / United States Z99 CA999999 / ImNIH / Intramural NIH HHS / United States HHSN261201700005I / CA / NCI NIH HHS / United States HHSN261200800001C / RC / CCR NIH HHS / United States HHSN261201700005C / CA / NCI NIH HHS / United States HHSN261200800001E / CA / NCI NIH HHS / United States U24 CA210969 / CA / NCI NIH HHS / United States U24 CA210988 / CA / NCI NIH HHS / United States |
Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment.
Similar Publications
Single cell dual-omic atlas of the human developing retina. Nat Commun. 2024;15(1):6792. | .
Loss of symmetric cell division of apical neural progenitors drives DENND5A-related developmental and epileptic encephalopathy. Nat Commun. 2024;15(1):7239. | .
The DNA methylome of pediatric brain tumors appears shaped by structural variation and predicts survival. Nat Commun. 2024;15(1):6775. | .